Indivior Pharmaceuticals, Inc. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-03: Disclosure Non Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-03: Disclosure Non Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-03: Disclosure Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-05-05: Disclosure Non Rule10b51Arr Adopted; Period 2026-01-01..2026-03-31; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-03 10-Q | Non Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-03 10-Q | Non Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-03 10-Q | Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-05-05 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-05 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-04-30 DEF 14A | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-30 DEF 14A | Pay versus Performance Table | 2025-01-01..2025-12-31 | Year Summary Compensation Table Total for Jack Khattar (1) ($) Compensation Actually Paid to Jack Khattar (1)(2)(3) ($) Average Summary Compensation Table Total for Non-PEO NEOs (1) ($) Average Compensation Actually Paid to Non-PEO NEOs (1)(2)(3) ($) Value of Initial Fixed $100 I… | |
| 2026-04-30 DEF 14A | Named Executive Officers Footnote | 2025-01-01..2025-12-31 | 1. Jack Khattar was our PEO for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below. 2021 2022-2025 Timothy C. Dec Timothy C. Dec Jonathan Rubin, MD Jonathan Rubin, MD Padmanabh P. Bhatt, Ph.D. Padmanabh P. Bhatt, Ph… | |
| 2026-04-30 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2025-01-01..2025-12-31 | 3. Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the S… | |
| 2026-04-30 DEF 14A | Adjustment To PEO Compensation Footnote | 2025-01-01..2025-12-31 | 3. Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the S… | |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$13.57M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $21.80M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$10.77M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $7.36M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$829.06K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $1.68M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$922.58K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $603.25K |
| 2026-04-30 DEF 14A | Eqty Awrds Adjustment Footnote | 2025-01-01..2025-12-31 | The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables: Year Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Jack Khattar ($) Change in Fair Value from Last Da… | |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $15.24M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $4.41M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $2.16M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $10.50M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$2.10M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $1.38M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$2.41M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $1.10M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $513.39K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $105.72K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$37.97K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $1.01M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$168.51K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $58.72K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$293.44K |
| 2026-04-30 DEF 14A | Peer Group Issuers Footnote | 2025-01-01..2025-12-31 | 5. The Peer Group TSR set forth in this table utilizes the Nasdaq Biotechnology Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the year ended December 31, 2025. The comparison assumes $100 was invested for the p… | |
| 2026-04-30 DEF 14A | Non Gaap Measure Description | Measure: 1 | 2025-01-01..2025-12-31 | 6. We determined Gross Product Sales to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and Non-PEO NEOs in 2025, 2024, 2023, and 2022. This performance measure may not have been the most important financial performance me… |
| 2026-04-30 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2025-01-01..2025-12-31 | ||
| 2026-04-30 DEF 14A | Total Shareholder Return Vs Peer Group | 2025-01-01..2025-12-31 | ||
| 2026-04-30 DEF 14A | Compensation Actually Paid Vs Net Income | 2025-01-01..2025-12-31 | ||
| 2026-04-30 DEF 14A | Compensation Actually Paid Vs Company Selected Measure | 2025-01-01..2025-12-31 | ||
| 2026-04-30 DEF 14A | Tabular List Table | 2025-01-01..2025-12-31 | Tabular List of Most Important Financial Performance Measures The following table presents the financial performance measures that the Company considers the most important in linking Compensation Actually Paid to our PEO and Non-PEO NEOs for 2025 to Company performance. The measures in this table ar… | |
| 2026-04-30 DEF 14A | Award Timing MNPI Disclosure | 2025-01-01..2025-12-31 | At a regularly scheduled annual meeting of the Company’s Board of Directors and Compensation Committee held in late February or early March of each year, it is the Board’s and Compensation Committee’s long-standing practice to review the Company’s results for the most recently completed fiscal year,… | |
| 2026-04-30 DEF 14A | Award Timing Method | 2025-01-01..2025-12-31 | Accordingly, the grant date for those equity awards has always been the date of the late February or early March meeting of the Compensation Committee and Board of Directors. The meeting date is generally set at least a year in advance. This timing coincides with the Company’s calendar-year-based pe… | |
| 2026-04-30 DEF 14A | Award Timing Predetermined | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-30 DEF 14A | Awards Close To MNPI Disclosure Table | 2025-01-01..2025-12-31 | Name Grant Date Number of Securities Underlying the Award Exercise Price of the Award Grant Date Fair Value of the Award Percentage Change in the Closing Market Price of the Securities Underlying the Award Between the Trading Day Ending Immediately Prior to the Disclosure of Mate… | |
| 2026-04-30 DEF 14A | Award Undrlyg Securities | Individual: JackKhattar | 2025-02-20 | 331,660 |
| 2026-04-30 DEF 14A | Award Exrc Price | Individual: JackKhattar | 2025-02-20 | 34.59 |
| 2026-04-30 DEF 14A | Award Grant Date Fair Value | Individual: JackKhattar | 2025-02-20 | $21.20 |
| 2026-04-30 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: JackKhattar | 2025-02-20 | 5.7 |
| 2026-04-30 DEF 14A | Award Undrlyg Securities | Individual: TimothyCDec | 2025-02-19 | 40,000 |
| 2026-04-30 DEF 14A | Award Exrc Price | Individual: TimothyCDec | 2025-02-19 | 33.52 |
| 2026-04-30 DEF 14A | Award Grant Date Fair Value | Individual: TimothyCDec | 2025-02-19 | $20.56 |
| 2026-04-30 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: TimothyCDec | 2025-02-19 | 5.7 |
| 2026-04-30 DEF 14A | Award Undrlyg Securities | Individual: JonathanRubin | 2025-02-19 | 20,000 |
| 2026-04-30 DEF 14A | Award Exrc Price | Individual: JonathanRubin | 2025-02-19 | 33.52 |
| 2026-04-30 DEF 14A | Award Grant Date Fair Value | Individual: JonathanRubin | 2025-02-19 | $20.56 |
| 2026-04-30 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: JonathanRubin | 2025-02-19 | 5.7 |
| 2026-04-30 DEF 14A | Award Undrlyg Securities | Individual: PadmanabhBhatt | 2025-02-19 | 20,000 |
| 2026-04-30 DEF 14A | Award Exrc Price | Individual: PadmanabhBhatt | 2025-02-19 | 33.52 |
| 2026-04-30 DEF 14A | Award Grant Date Fair Value | Individual: PadmanabhBhatt | 2025-02-19 | $20.56 |
| 2026-04-30 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: PadmanabhBhatt | 2025-02-19 | 5.7 |
| 2026-04-30 DEF 14A | Award Undrlyg Securities | Individual: FrankMottola | 2025-02-19 | 20,000 |
| 2026-04-30 DEF 14A | Award Exrc Price | Individual: FrankMottola | 2025-02-19 | 33.52 |
| 2026-04-30 DEF 14A | Award Grant Date Fair Value | Individual: FrankMottola | 2025-02-19 | $20.56 |
| 2026-04-30 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: FrankMottola | 2025-02-19 | 5.7 |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | |
| 2026-03-02 10-K | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-03-02 10-K | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-03-02 10-K | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-03-02 10-K | Material Terms Of Trading Arrangement | 2025-10-01..2025-12-31 | Name and Title of Director or Officer Rule 10b5-1 Trading Arrangement (1) Trading Arrangement Adopted or Terminated Date of Adoption or Termination Duration of Trading Arrangement Aggregate Number of Securities to be Purchased Pursuant to Trading Arrangement Aggregate Number of Securities to be Sold… | |
| 2026-03-02 10-K | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |